CAMP logo

CAMP4 Therapeutics (CAMP) Company Overview

Profile

Full Name:

CAMP4 Therapeutics

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 11, 2024

Indexes:

Not included

Description:

CalAmp is a technology company that provides solutions for tracking and managing vehicles and assets. They use GPS and wireless communication to help businesses improve efficiency, reduce costs, and enhance safety. Their services are used in various industries, including transportation, logistics, and fleet management.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Jun 27, 2024

Recent annual earnings:

Jun 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 2, 2024

Analyst ratings

Recent major analysts updates

Nov 5, 24 William Blair
Outperform
Nov 5, 24 Piper Sandler
Overweight
Nov 5, 24 Leerink Partners
Outperform
Nov 5, 24 JP Morgan
Overweight
Jan 11, 24 Goldman Sachs
Sell
Oct 9, 23 Goldman Sachs
Sell
Oct 6, 23 Roth MKM
Buy
Oct 6, 23 Craig-Hallum
Hold
Aug 29, 23 Roth MKM
Buy
Jul 13, 23 Goldman Sachs
Sell

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

CAMP4 to Participate in Upcoming Investor Conferences
CAMP4 to Participate in Upcoming Investor Conferences
CAMP4 to Participate in Upcoming Investor Conferences
CAMP
globenewswire.comFebruary 6, 2025

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences:

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
CAMP
globenewswire.comJanuary 7, 2025

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today provided corporate updates and key objectives for 2025.

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMP
globenewswire.comDecember 2, 2024

CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced that management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference to be held at the Lotte New York Palace Hotel in New York City December 3rd – 5th, 2024.

CAMP4 Reports Third Quarter 2024 Financial Results
CAMP4 Reports Third Quarter 2024 Financial Results
CAMP4 Reports Third Quarter 2024 Financial Results
CAMP
globenewswire.comNovember 21, 2024

- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025- Entered strategic research collaboration with BioMarin valued at over $370M

CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP
benzinga.comNovember 5, 2024

In October, CAMP4 Therapeutics Corporation CAMP priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million in gross proceeds.

CAMP4 Announces Pricing of Initial Public Offering
CAMP4 Announces Pricing of Initial Public Offering
CAMP4 Announces Pricing of Initial Public Offering
CAMP
globenewswire.comOctober 10, 2024

CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the pricing of its initial public offering of 6,820,000 shares of its common stock at an initial public offering price of $11.00 per share. All of the shares are being offered by CAMP4. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. CAMP4's common stock is expected to begin trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol “CAMP”. The offering is expected to close on October 15, 2024, subject to the satisfaction of customary closing conditions. In addition, CAMP4 has granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Camp4 Therapeutics Targets IPO On Early Positive Results
Camp4 Therapeutics Targets IPO On Early Positive Results
Camp4 Therapeutics Targets IPO On Early Positive Results
CAMP
seekingalpha.comOctober 1, 2024

Camp4 Therapeutics is seeking $75 million in an IPO to fund the advancement of its clinical-stage biopharma programs targeting genetic disorders. CAMP's lead candidate, CMP-CPS-001, has shown positive Phase 1 safety results for treating urea cycle disorders, with no concerning safety trends observed. The urea cycle disorders market is moderate in size, with a low expected growth rate, but Camp4 aims to broaden into larger markets.

CalAmp Industrial IoT Gateway Named an OEM Off-Highway 2024 Top New Product Award Recipient
CalAmp Industrial IoT Gateway Named an OEM Off-Highway 2024 Top New Product Award Recipient
CalAmp Industrial IoT Gateway Named an OEM Off-Highway 2024 Top New Product Award Recipient
CAMP
globenewswire.comSeptember 24, 2024

CARLSBAD, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- OEM Off-Highway, the nationally recognized magazine serving product development teams for mobile OEMs globally, has selected the HMU-3640LB Industrial IoT Gateway as one of the favored new mobile on- and off-road equipment products of 2024.

CalAmp Welcomes Thomas Ayers as General Manager of Edge Device Business
CalAmp Welcomes Thomas Ayers as General Manager of Edge Device Business
CalAmp Welcomes Thomas Ayers as General Manager of Edge Device Business
CAMP
globenewswire.comAugust 29, 2024

CARLSBAD, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- CalAmp Corp. (“CalAmp”), a telematics company that provides products and solutions that help organizations monitor, track and protect vital assets, is pleased to announce the appointment of Thomas Ayers as General Manager of its Edge Device business. In this role, Ayers will spearhead the growth and innovation of CalAmp's edge device portfolio, leveraging his extensive expertise in hardware development and leading-edge technology.

CAMP SNOOPY GETS BIGGER, BETTER, AND SNOOPY-ER IN 2025
CAMP SNOOPY GETS BIGGER, BETTER, AND SNOOPY-ER IN 2025
CAMP SNOOPY GETS BIGGER, BETTER, AND SNOOPY-ER IN 2025
CAMP
globenewswire.comAugust 8, 2024

Carowinds' Historic Investment Includes Two Major New Family Attractions Carowinds' Historic Investment Includes Two Major New Family Attractions

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for CAMP4 Therapeutics?
  • Does CAMP4 Therapeutics pay dividends?
  • What sector is CAMP4 Therapeutics in?
  • What industry is CAMP4 Therapeutics in?
  • What country is CAMP4 Therapeutics based in?
  • When did CAMP4 Therapeutics go public?
  • Is CAMP4 Therapeutics in the S&P 500?
  • Is CAMP4 Therapeutics in the NASDAQ 100?
  • Is CAMP4 Therapeutics in the Dow Jones?
  • When was CAMP4 Therapeutics's last earnings report?
  • When does CAMP4 Therapeutics report earnings?
  • Should I buy CAMP4 Therapeutics stock now?

What is the ticker symbol for CAMP4 Therapeutics?

The ticker symbol for CAMP4 Therapeutics is NASDAQ:CAMP

Does CAMP4 Therapeutics pay dividends?

No, CAMP4 Therapeutics does not pay dividends

What sector is CAMP4 Therapeutics in?

CAMP4 Therapeutics is in the Healthcare sector

What industry is CAMP4 Therapeutics in?

CAMP4 Therapeutics is in the Biotechnology industry

What country is CAMP4 Therapeutics based in?

CAMP4 Therapeutics is headquartered in United States

When did CAMP4 Therapeutics go public?

CAMP4 Therapeutics's initial public offering (IPO) was on October 11, 2024

Is CAMP4 Therapeutics in the S&P 500?

No, CAMP4 Therapeutics is not included in the S&P 500 index

Is CAMP4 Therapeutics in the NASDAQ 100?

No, CAMP4 Therapeutics is not included in the NASDAQ 100 index

Is CAMP4 Therapeutics in the Dow Jones?

No, CAMP4 Therapeutics is not included in the Dow Jones index

When was CAMP4 Therapeutics's last earnings report?

CAMP4 Therapeutics's most recent earnings report was on Jun 27, 2024

When does CAMP4 Therapeutics report earnings?

The date for CAMP4 Therapeutics's next earnings report has not been announced yet

Should I buy CAMP4 Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions